Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.

Helius Medical Technologies, Inc.

A neurotech company focused on neurologic deficits using non-implantable platform technologies that amplify the brain's ability to compensate and promote neuroplasticity, improving the lives of people dealing with neurologic diseases.

Helius Medical Technologies

Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brain’s ability to compensate and promotes neuroplasticity, aiming to improve the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS).

PoNS™, short for Portable Neuromodulation Stimulator, is an innovative medical device. It is inclusive of a controller and mouthpiece, that delivers mild stimulation to the surface of the tongue. This stimulation triggers a flow of neural impulses to the brain structures that control balance and gait. PoNS is meant to be used in conjunction with supervised therapeutic activity, referred to as, PoNS Therapy™. Use of the device while engaging in movement and coordination tasks promotes neuromodulation, activating brain pathways to help improve balance and gait.

PoNS is authorized in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.

PoNS is authorized in Canada for three indications: (i) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy; and (ii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy; and (iii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from stroke, to be used in conjunction with physical therapy. 

PoNS is authorized in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait.

PoNS™ (ponstherapy.com), short for Portable Neuromodulation Stimulator, is an innovative medical device. It is inclusive of a controller and mouthpiece, that delivers mild stimulation to the surface of the tongue. This stimulation triggers a flow of neural impulses to the brain structures that control balance and gait. PoNS is meant to be used in conjunction with supervised therapeutic activity, referred to as, PoNS Therapy™. Use of the device while engaging in movement and coordination tasks promotes neuromodulation, activating brain pathways to help improve balance and gait.

Studies have shown that individuals with multiple sclerosis who completed 14-weeks of PoNS Therapy® (www.ponstherapy.com) have seen improvements in their gait scores of an average of 8 points. 

An 8-point improvement in your gait can mean improving your walking so you can RSVP “yes” to the wedding, book the vacation you have been putting off, or go for a walk on the beach. 

Learn more at www.ponstherapy.com.

Individual results and experiences may vary. Speak to your physician to determine if PoNS is right for you.

After 14-weeks of PoNS Therapy® (www.ponstherapy.com), 100% of participants with multiple sclerosis saw a 
4-point improvement in dynamic gait index (DGI) scores, with an average of almost 8 points and 40% even saw improvements above 8 points. 

We encourage you to set your sights high – AIM FOR EIGHT points of improvement. 

Learn more: https://lnkd.in/e6Ja8tva

Individual results and experiences may vary. Speak to your physician to determine if PoNS® is right for you. 

#PoNS #PoNSTherapy #Helius #PortableNeuromodulationStimulator #physicaltherapy #GetBackInStepWithLife #MultipleSclerosis #MS #PhysicalRehabilitation #Walking

PoNS® (www.ponstherapy.com) is committed to improving walking ability across the country.  

Keep an eye out—we hope to bring PoNS to those in the US with gait deficit due to stroke soon.

Learn more: https://lnkd.in/eWPe7Tuy

#PoNS #PoNSTherapy #PoNSDevice #Helius #PortableNeuromodulationStimulator #physicaltherapy #GetBackInStepWithLife #MultipleSclerosis #MS #PhysicalRehabilitation #Walking #Stroke

PoNS® (www.ponstherapy.com) proudly supports our Veterans!

Discover how we're dedicated to helping Veterans with multiple sclerosis improve their gait on our new page. 

Learn more today: https://lnkd.in/eTb9Zfwf

#PoNS #PoNSTherapy #PoNSDevice #Helius #PortableNeuromodulationStimulator #GetBackInStepWithLife #PhysicalTherapy #MS #MultipleSclerosis #Veterans #VA #USVeterans #Vet

After using PoNS™ (www.ponstherapy.ca) for 14 weeks, 28% of people with stroke were no longer at fall risk. Routine physical therapy usually only provides a meaningful shift in fall risk for 1-3% of patients. 

Learn more about PoNS Therapy™: www.ponstherapy.ca

Individual results and experiences vary. Patients should talk to their doctor to see if PoNS is right for them. 


#PoNS #PoNSTherapy #PoNSDevice #Helius #PortableNeuromodulationStimulator #physicaltherapy #GetBackInStepWithLife #TraumaticBrainInjury #TBI #Stroke #MultipleSclerosis #MS #PhysicalRehabilitation #Walking #Neurostimulation #FallRisk

	Mar '14	Mar '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables			2.16M -	3.48M 60.99%	2.39M 31.24%	1.68M 29.93%	747K 55.43%	1.07M 43.11%	627K 41.35%	531K 15.31%
accumulated other comprehensive income loss		-971.64K -	-1.73M 77.84%	47K 102.72%	-591K 1,357.45%	-902K 52.62%	-1.10M 21.84%	-1.13M 2.37%	-388K 65.51%	-673K 73.45%
cash and cash equivalents	9 -	418.89K 4,654,266.67%	2.67M 537.16%	5.56M 108.39%	25.58M 359.96%	5.46M 78.66%	3.33M 38.98%	11.01M 230.38%	14.55M 32.20%	5.18M 64.38%
cash and short term investments	9 -	796.89K 8,854,266.67%	2.67M 234.93%	5.56M 108.39%	25.58M 359.96%	5.46M 78.66%	3.33M 38.98%	11.01M 230.38%	14.55M 32.20%	5.18M 64.38%
common stock	9 -	16.36M 181,756,488.89%	30.90M 88.88%	52.23M 69.05%	26K 99.95%	31K 19.23%	1K 96.77%	4K 300%	28K 600%	1K 96.43%
deferred revenue				233K -		430K -	281K 34.65%	148K 47.33%	27K 81.76%	43K 59.26%
deferred revenue non current						245K -	220K 10.20%	193K 12.27%	175K 9.33%	128K 26.86%
deferrred tax liabilities non current
goodwill						1.24M -	759K 38.89%	763K 0.53%
goodwill and intangible assets						1.82M -	1.29M 29.50%	1.10M 14.77%	140K 87.23%	24K 82.86%
intangible assets						582K -	527K 9.45%	333K 36.81%	140K 57.96%	24K 82.86%
inventory					392K -	598K 52.55%	389K 34.95%	476K 22.37%	589K 23.74%	457K 22.41%
long term debt						465K -	32K 93.12%		56K -	12K 78.57%
long term investments
net debt	-9 -	-418.89K 4,654,266.67%	-2.67M 537.16%	-5.56M 108.39%	-25.58M 359.96%	-4.82M 81.15%	-3.24M 32.81%	-11.00M 239.57%	-14.44M 31.24%	-5.13M 64.51%
net receivables		8.83K -	225K 2,447.27%	704K 212.89%	275K 60.94%	574K 108.73%	230K 59.93%	251K 9.13%	343K 36.65%	637K 85.71%
other assets
other current assets		410.62K -	556K 35.40%	352K 36.69%	711K 101.99%	610K 14.21%	735K 20.49%	862K 17.28%	1.22M 41.07%	1.16M 4.44%
other current liabilities		1.20M -	4.73M 295.14%	9.58M 102.37%	15.58M 62.67%	1.52M 90.22%	1.34M 12.27%	1.43M 7.18%	1.28M 10.68%	1.26M 1.56%
other liabilities			-2.16M -	-3.71M 71.77%	-2.39M 35.56%
other non current assets				18K -	312K 1,633.33%	18K 94.23%
other non current liabilities		1.58M -	2.16M 36.65%	3.71M 71.77%	2.39M 35.56%				6.92M -	3.32M 51.96%
othertotal stockholders equity		1.53M -	5.73M 274.56%	6.60M 15.18%	105.41M 1,496.65%	111.48M 5.76%	123.87M 11.12%	149.41M 20.62%	159.62M 6.83%	162.98M 2.11%
preferred stock
property plant equipment net				173K -	554K 220.23%	1.26M 128.16%	576K 54.43%	412K 28.47%	450K 9.22%	230K 48.89%
retained earnings		-18.48M -	-38.34M 107.50%	-66.37M 73.08%	-94.99M 43.13%	-104.77M 10.30%	-118.90M 13.49%	-137.03M 15.25%	-151.11M 10.27%	-159.96M 5.86%
short term debt				1.01M -		172K -	59K 65.70%	3K 94.92%	54K 1,700%	45K 16.67%
short term investments		378K -
tax assets
tax payables
total assets	9 -	1.22M 13,514,866.67%	3.45M 183.64%	6.81M 97.36%	27.83M 308.68%	10.35M 62.82%	6.55M 36.73%	14.10M 115.40%	17.29M 22.59%	7.69M 55.50%
total current assets	9 -	1.22M 13,514,866.67%	3.45M 183.64%	6.62M 91.83%	26.96M 307.39%	7.24M 73.14%	4.68M 35.30%	12.59M 168.82%	16.70M 32.58%	7.44M 55.45%
total current liabilities		1.20M -	6.89M 475.55%	14.30M 107.41%	17.97M 25.69%	3.80M 78.85%	2.42M 36.24%	2.65M 9.45%	1.99M 25.07%	1.88M 5.48%
total debt						637K -	91K 85.71%	3K 96.70%	110K 3,566.67%	57K 48.18%
total investments		378K -
total liabilities		2.78M -	6.89M 148.05%	14.30M 107.41%	17.97M 25.69%	4.51M 74.90%	2.68M 40.69%	2.85M 6.35%	9.14M 221.01%	5.34M 41.53%
total liabilities and stockholders equity	9 -	1.22M 13,514,866.67%	3.45M 183.64%	6.81M 97.36%	27.83M 308.68%	10.35M 62.82%	6.55M 36.73%	14.10M 115.40%	17.29M 22.59%	7.69M 55.50%
total non current assets				191K -	866K 353.40%	3.11M 258.66%	1.86M 40.05%	1.51M 19.01%	590K 60.88%	254K 56.95%
total non current liabilities		1.58M -	2.16M 36.65%	3.71M 71.77%	2.39M 35.56%	710K 70.32%	252K 64.51%	193K 23.41%	7.15M 3,603.63%	3.46M 51.55%
total stockholders equity	9 -	-1.56M 17,365,666.67%	-3.44M 120.36%	-7.49M 117.48%	9.85M 231.56%	5.83M 40.79%	3.87M 33.66%	11.26M 190.78%	8.15M 27.59%	2.35M 71.17%

COM:HELIUSMEDICAL

Helius Medical Technologies

Last Close

0.47

21/11 21:00

Market Cap

2.54M

Beta: -

Volume Today

57.45K

Avg: -

Preview